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We appreciate the interest of Dr. Mielewczik and colleagues in the
C-CURE (Cardiopoietic stem Cell therapy in heart failURE) trial.
As outlined in our paper (1), feasibility and safety were the primary
endpoints in this ﬁrst-in-man study that assessed cardiogenically-
oriented, autologous bone marrow-derived mesenchymal stem cell
therapy in chronic heart failure. The technology and study ﬁndings
were reviewed in the scientiﬁc literature in the context of advances
in regenerative medicine (2,3). We would like here to conﬁrm that
the C-CURE trial was designed, planned, executed, analyzed, and
presented according to best standards in innovative clinical
research. There are no inconsistencies in the C-CURE trial, as will
be further illustrated in the following text. Following this initial
study, a larger trial designed and powered to evaluate efﬁcacy was
approved and launched (the CHART-1 [Congestive Heart Failure
CArdiopoietic Regenerative Therapy] trial) (4). Herein, we directly
address the Letter to the Editor by Dr. Mielewczik and colleagues
that noted interest in the C-CURE trial but raised a number of
questions.
How many patients were randomized? Counts range from
45 to 48.
Informed consent was requested from a total of 48 patients. One
patient refused participation, and of the remaining 47 randomized
subjects, 2 patients were subsequently excluded based on criteria
identiﬁed prior to bone marrow harvest (1 patient was diagnosed with
a left ventricular aneurysm; a second patient developed a left ventricular
thrombus).Therewas an imprecision in the textwhere 48 patientswho
entered the consent process are described as “randomized.” It would
have been more precise to state, “Consent was requested from 48
patients, and 47 were randomized.” Figure 1 in our paper (1) depicts
the ﬂow of the study, presenting its stepwise execution.
The authors’ corporate website currently states that
randomization was 1:1 but Figure 1 in the paper (1) shows
counts close to 1:2; conversely, at AHA 2011, the authors said
that randomization was 2:1 but reported counts that were close
to 1:1. Can the authors please clarify the randomization ratio?
Randomization (2:1) was executed by a site-independent
centralized process. Of note, the authors do not have a corporate
website. The website of Cardio3 BioSciences, the sponsor of the
study, indicated at 1 stage a 1:1 ratio. This error has been corrected.
Once randomized to 1 arm, did any patient’s data appear
under the heading of the opposite arm? Were some patients
allocated to arms by routes other than randomization to those
arms? Are baseline characteristics and result data regarding the
trial arms, as randomized, available?
Protocol-deﬁned analysis, in which all patients not receiving cell
therapy were placed in the control arm (n ¼ 24) and all those
receiving cell therapy were placed in the cell therapy arm (n¼ 21), is
presented in Online Figure 13 of our paper (1), with patient
demographics shown in Table 1 (1). The paper also presents in main
ﬁgures a complementary analysis, as advised in the peer-reviewprocess, that maintains the randomization schedule with analysis
taking into account clinical inclusion/cell release criteria (n ¼ 15
control arm; n ¼ 21 cell therapy arm). We here include an updated
demographics table with baseline characteristics pertinent to both
analyses (Table 1). Neither the 15 of 21 nor the 24 of 21 baseline
comparisons reveal signiﬁcant differences in populations, nor do
they change the outcome of efﬁcacy signals. The revised table
corrects for original typographical errors, which had no material
impact on trial ﬁndings, interpretations, or conclusions (Table 1).
The primary endpoint was pre-speciﬁed to be radionuclide
ejection fraction, but its results do not appear in the paper. A
new primary endpoint is described in the paper. Did all authors
agree on this change, and when?
Safety and feasibility are the primary endpoints of the C-CURE
trial, as reported in the paper (1). The initial design of the C-
CURE trial included a safety and feasibility phase (termed Stage A;
n ¼ 45 patients) to be potentially followed by an efﬁcacy phase with
a primary endpoint of radionuclide ejection fraction (EF) (termed
Stage B; n ¼ 195 patients). The Stage A part of the study had
a built-in “go/no go” decision at the 3-month follow-up visit.
Indeed, at the 3-month time point, the procedure was deemed
feasible and safe. Yet, in line with advice received from regulatory
authorities indicating that a properly powered study assessing
efﬁcacy in heart failure would require inclusion of outcome
endpoints beyond a focus on cardiac function, the steering
committee communicated to study sites the decision not to proceed
with Stage B and limited the C-CURE trial to a safety/feasibility
study, completing Stage A per protocol.
Regarding the data presented in the paper (1), its Online
Appendix, and the previous trial reports (see the Online
Appendix for citations), which of these various conﬂicting
versions are correct regarding ejection fraction, end-systolic
volume, end-diastolic volume, New York Heart Association
functional class, quality of life, and walk distance?
Data reported in the paper are correct (1). Earlier abstracts or
initial oral presentations are considered preliminary, providing
reports of datasets not yet monitored for source data veriﬁcation per
good clinical practice guidelines, not yet sanctioned or adjudicated
by the independent data safety monitoring board (DSMB), and not
subject to peer review.
Fewer of certain events, such as arrhythmias, are reported in
the current narrative than in previous ones. Could the authors
clarify how many stem cell recipients died?
This is a request for clariﬁcation regarding the description of
adverse events and patient deaths as it pertains to preliminary
reports. Initial communications presented data in various forms, for
example, the number of arrhythmic events versus the number of
patients with arrhythmia. The paper reports those data adjudicated
by the DSMB (1). For example, the number of episodes versus the
number of patients suffering from arrhythmic events was distin-
guished in the paper (1). Furthermore, as stated in the paper (1),
1 patient died in the cell-treated group of the randomized C-CURE
trial. This followed an elective cardiac transplantation and post-
operative sepsis. In a separate nonrandomized pilot study, the
Swiss Feasibility Study, which is distinct from the C-CURE trial,
1 patient died prior to being treated. The event is thus not reported
in the paper, while this information may have been presented in
earlier presentations to represent the totality of experience.
Table 1 Patient Demographics, Cardiac History, and Medication Proﬁle in Control and Cell Therapy Cohorts
Control (N ¼ 15) Control (N ¼ 24) Cell Therapy (N ¼ 21) p Value 15/21 p Value 24/21
Age, yrs 58.7  8.2 59.5  8.0 55.3 10.4 0.424 0.234
Sex, M/F 13/2 22/2 19/2 0.720 0.889
Family history, CAD 9 (64)* 12 (52)* 15 (71) 0.657 0.19
Smoking
Former 9 (60) 18 (75) 11 (52) 0.650 0.114
Current 5 (33) 5 (21) 5 (24) 0.529 0.811
Arterial hypertension 7 (47) 13 (54) 9 (43) 0.820 0.450
Diabetes mellitus 4 (27) 8 (33) 4 (19) 0.588 0.280
on diet 1 (7) 3 (13) 1 (5) 0.806 0.363
NIDDM 1 (7) 2 (8) 2 (10) 0.760 0.889
IDDM 2 (13) 3 (13) 1 (5) 0.359 0.363
Hypercholesterolemia 15 (100) 24 (100) 16 (76) 0.042 0.011
on diet 1 (7) 1 (4) 0 (0) 0.230 0.344
on statins 14 (93) 23 (96) 16 (76) 0.174 0.053
Cardiac history
ICD implant 3 (20) 8 (38) 10 (48) 0.089 0.329
CRT implant 1 (7) 2 (8) 1 (5) 0.801 0.632
PCI 14 (93) 21 (38) 17 (81) 0.290 0.545
CABG 3 (20) 8 (33) 4 (19) 0.943 0.280
Ml 15 (100) 23 (96) 21 (100) N/A 0.344
Other cardiac surgery 1 (7) 2 (8) 2 (10) 0.760 0.889
Sustained VT or VF 5 (33) 9 (33) 4 (19) 0.329 0.173
Atrial Fibrillation 2 (13) 3 (13) 4 (19) 0.650 0.545
Medication proﬁle
ACE inhibitor 13 (87) 19 (79) 18 (86) 0.935 0.567
ATR1-blocker 2 (13) 4 (17) 3 (14) 0.935 0.826
Beta-blocker 11 (73) 19 (79) 20 (95) 0.061 0.114
Diuretic agent 13 (87) 19 (79) 18 (86) 0.935 0.567
Antiplatelet agent 15 (100) 23 (96) 20 (86) 0.391 0. 923
Statins 14 (93) 23 (96) 17 (8l) 0.290 0.113
Hypoglycemic agent 2 (13) 4 (17) 2 (10) 0.720 0.482
Antiarrhythmic agent 2 (13) 4 (17) 9 (43) 0.058 0.531
Calcium antagonist 1 (7) 1 (4) 3 (14) 0.473 0.234
Nitrate or molsidomine 5 (33) 7 (29) 2 (10) 0.075 0.100
*Family history of CAD of one control was not available.
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2455It would be extremely helpful if the authors could resolve
these and other uncertainties to aid interpretation (see Online
Appendix for a detailed list of discrepancies and citations).
Additional information is provided as a reply to the Online
Appendix (3).
In conclusion, the C-CURE study is the ﬁrst clinical study to
evaluate lineage-speciﬁed stem cells as a potential therapeutic
option in chronic disease (1). Speciﬁcally, the C-CURE trial
achieved clinical translation of the cardiopoiesis platform (5–9),
adding a lineage-specifying step to existing cell therapy paradigms
in order to prime patient-derived naive stem cells for enhanced
therapeutic impact in the failing heart. This initial experience is
now being tested in the larger CHART-1 study (4). These studies
exemplify a broad range of ongoing efforts in translating advances
in regenerative science into novel therapies.Jozef Bartunek, MD, PhD
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APPENDIX
For additional issues and responses, please see the online version of this
article.
